Welcome to our dedicated page for Skylight Health Group news (Ticker: SLHGF), a resource for investors and traders seeking the latest updates and insights on Skylight Health Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Skylight Health Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Skylight Health Group's position in the market.
Skylight Health Group has received an extension from the TSX Venture Exchange to complete a US$5 million financing through convertible debentures by December 21, 2022. This financing is crucial for the Company's efforts to transition towards value-based care in the U.S. healthcare system, focusing on improving patient outcomes and financial performance. The terms remain unchanged from a prior announcement. The Company aims to assist practices in moving from a fee-for-service to a value-based care model.
Skylight Health Group Inc. (OTCQX:SLHGF) reported strong financial results for Q3 2022, with revenues reaching $20.8 million, a 152% year-over-year growth and a 30% increase from the previous quarter. The net loss decreased by 16% to $4.3 million, while adjusted EBITDA loss improved by 27% to $3.97 million. The company is transitioning to a full-risk value-based care model, expecting further operational improvements and adjusted EBITDA break-even by the end of 2022. In addition, Skylight has secured new contracts for Medicare Advantage in Florida, further enhancing growth prospects.
Skylight Health Group (TSXV:SLHG; OTCQX:SLHGF) will release its financial results for Q3 2022 on November 16, 2022, after market close. The company aims to transition patients into value-based care in the U.S. healthcare system, enhancing health outcomes through technology and analytics. A conference call is scheduled for November 17, 2022, at 8:00 AM EDT to discuss these results and the company’s outlook.
Skylight Health Group (TSXV:SLHG; OTCQX:SLHGF) has announced a strategic investment of USD 5 million from a U.S. healthcare investment firm, structured as a 0% interest convertible debenture. The initial tranche of USD 3.37 million has been completed, with the second tranche of USD 1.63 million expected in 30 days. The funds will support the company's growth towards profitability, following improved EBITDA performance and an expanding Medicare Advantage portfolio. A dividend of $0.1927 per share for Series A Preferred Shares will also be paid on November 21, 2022.